venBio
View Older Stories View More Recent Stories
-
Form 4 Akero Therapeutics, Inc. For: Feb 28 Filed by: venBio Global Strategic GP II, L.P.
-
Form 13F-HR venBio Partners LLC For: Dec 31
-
ALX Oncology Announces Closing of $105 Million Series C Financing
-
Form 4 Akero Therapeutics, Inc. For: Feb 06 Filed by: venBio Global Strategic GP II, L.P.
-
Form SC 13D/A Akero Therapeutics, Inc. Filed by: venBio Global Strategic Fund II L.P.
-
NorthSea Therapeutics Announces US $40 Million Series B Financing to Complete Phase IIb ICONA study in NASH and to Advance Two Additional SEFAs into the Clinic
-
Form 4 Akero Therapeutics, Inc. For: Jan 02 Filed by: venBio Global Strategic GP II, L.P.
-
Form 13F-HR venBio Partners LLC For: Sep 30
-
Swift Health Systems Raises $45 Million in Series C Funding
-
Evotec Reaches Milestone In Integrated Drug Discovery And Development Partnership With Aeovian
-
Aeovian Pharmaceuticals Raises $37 Million Series A Financing to Advance Selective mTORC1 Inhibitors into the Clinic for Rare and Age-Related Diseases
-
Pharvaris Announces $66 Million Series B Financing to Advance the Clinical Development of an Oral Therapy for Hereditary Angioedema
-
Form 13F-HR venBio Partners LLC For: Jun 30
-
Athenex, Inc. Announces Second Quarter 2019 Financial Results, Positive Phase III Results on Oral Paclitaxel plus Encequidar and Increased Product Sales Guidance
-
Athenex, Inc. Announces Second Quarter 2019 Financial Results, Positive Phase III Results on Oral Paclitaxel plus Encequidar and Increased Product Sales Guidance
-
Form SC 13D Akero Therapeutics, Inc. Filed by: venBio Global Strategic Fund II L.P.
-
Form 4 Akero Therapeutics, Inc. For: Jun 24 Filed by: venBio Global Strategic GP II, Ltd.
-
Form 13F-HR venBio Partners LLC For: Mar 31
-
Athenex, Inc. Announces First Quarter 2019 Financial Results and Provides Corporate Update
-
Athenex, Inc. Announces First Quarter 2019 Financial Results and Provides Corporate Update
-
Athenex (ATNX) Announces $100 Million Private Placement of Common Stock
-
Athenex Announces $100 Million Private Placement
-
Athenex Announces $100 Million Private Placement
-
Arrakis Therapeutics Announces $75 Million Series B Financing to Advance a New Class of Small-Molecule Medicines Targeting RNA
-
Form SC 13D PRECISION BIOSCIENCES Filed by: venBio Global Strategic Fund, L.P.
-
Form 4 PRECISION BIOSCIENCES For: Apr 01 Filed by: venBio Global Strategic GP, L.P.
-
Form D/A venBio Global Strategic
-
Form 4 Mirati Therapeutics, For: Mar 18 Filed by: venBio Select Advisor LLC
-
Precision BioSciences Enters Into Private Convertible Note Financing
-
Form 4 Mirati Therapeutics, For: Feb 20 Filed by: venBio Select Advisor LLC
-
Form 13F-HR venBio Partners L.P. For: Dec 31
-
Form 13F-HR venBio Select Advisor For: Dec 31
-
Form SC 13G/A ALIMERA SCIENCES INC Filed by: venBio Select Advisor LLC
-
Form SC 13G/A Apellis Pharmaceuticals, Filed by: venBio Global Strategic Fund II L.P.
-
Form SC 13G/A Nabriva Therapeutics Filed by: venBio Global Strategic Fund II L.P.
-
Form SC 13G/A Teligent, Inc. Filed by: venBio Select Advisor LLC
-
Form SC 13G Xenon Pharmaceuticals Filed by: venBio Select Advisor LLC
-
Form SC 13G/A IOVANCE BIOTHERAPEUTICS, Filed by: venBio Select Advisor LLC
-
Form SC 13G/A FENNEC PHARMACEUTICALS Filed by: venBio Select Advisor LLC
-
Form SC 13G/A Intec Pharma Ltd. Filed by: venBio Select Advisor LLC
-
Form SC 13G/A AMICUS THERAPEUTICS, Filed by: venBio Select Advisor LLC
-
Form SC 13G TG THERAPEUTICS, INC. Filed by: venBio Select Advisor LLC
-
Form SC 13G/A Mirati Therapeutics, Filed by: venBio Select Advisor LLC
-
Form SC 13G BIODELIVERY SCIENCES Filed by: venBio Select Advisor LLC
-
Luby’s Announces Board Refreshment and Corporate Governance Changes
-
Checkmate Pharmaceuticals Announces CEO Transition and $22 Million Financing
-
Akero Therapeutics Announces $70 Million in New Financing to Advance Therapeutic Pipeline for NASH, Serious Metabolic Diseases
-
Akero Therapeutics Appoints Mark Iwicki to its Board of Directors
-
Impel NeuroPharma Closes $67.5 Million Series D Financing
-
Form 13F-HR venBio Select Advisor For: Sep 30

